Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16.

Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E, Campana D, Inaba H, Rubnitz JE, Ribeiro RC, Gruber TA, Raimondi SC, Khan RB, Yang JJ, Mullighan CG, Downing JR, Evans WE, Relling MV, Pui CH.

J Clin Oncol. 2019 Dec 10;37(35):3377-3391. doi: 10.1200/JCO.19.01692. Epub 2019 Oct 28.

PMID:
31657981
2.

Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431.

Mast KJ, Taub JW, Alonzo TA, Gamis AS, Mosse CA, Mathew P, Berman JN, Wang YC, Jones HM, Campana D, Coustan-Smith E, Raimondi SC, Hirsch B, Hitzler JK, Head DR.

Arch Pathol Lab Med. 2019 Aug 20. doi: 10.5858/arpa.2018-0526-OA. [Epub ahead of print]

PMID:
31429606
3.

Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.

Rubnitz JE, Lacayo NJ, Inaba H, Heym K, Ribeiro RC, Taub J, McNeer J, Degar B, Schiff D, Yeoh AE, Coustan-Smith E, Wang L, Triplett B, Raimondi SC, Klco J, Choi J, Pounds S, Pui CH.

J Clin Oncol. 2019 Aug 10;37(23):2072-2081. doi: 10.1200/JCO.19.00327. Epub 2019 Jun 27.

PMID:
31246522
4.

Reverse-engineering flow-cytometry gating strategies for phenotypic labelling and high-performance cell sorting.

Becht E, Simoni Y, Coustan-Smith E, Evrard M, Cheng Y, Ng LG, Campana D, Newell EW.

Bioinformatics. 2019 Jan 15;35(2):301-308. doi: 10.1093/bioinformatics/bty491.

PMID:
29931307
5.

Universal monitoring of minimal residual disease in acute myeloid leukemia.

Coustan-Smith E, Song G, Shurtleff S, Yeoh AE, Chng WJ, Chen SP, Rubnitz JE, Pui CH, Downing JR, Campana D.

JCI Insight. 2018 May 3;3(9). pii: 98561. doi: 10.1172/jci.insight.98561.

6.

Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies.

Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D.

Blood Adv. 2017 Nov 21;1(25):2348-2360. doi: 10.1182/bloodadvances.2017009928. eCollection 2017 Nov 28.

7.

Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial.

Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y, Gerbing RB, Wang YC, Alonzo TA, Campana D, Coustan-Smith E, Mathew P, Gamis AS.

Blood. 2017 Jun 22;129(25):3304-3313. doi: 10.1182/blood-2017-01-764324. Epub 2017 Apr 7.

8.

Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.

Huang YJ, Coustan-Smith E, Kao HW, Liu HC, Chen SH, Hsiao CC, Yang CP, Jaing TH, Yeh TC, Kuo MC, Lai CL, Chang CH, Campana D, Liang DC, Shih LY.

J Formos Med Assoc. 2017 Oct;116(10):774-781. doi: 10.1016/j.jfma.2016.12.002. Epub 2017 Jan 4.

9.

Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

Pui CH, Pei D, Raimondi SC, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE, Inaba H, Gruber TA, Leung WH, Yang JJ, Downing JR, Evans WE, Relling MV, Campana D.

Leukemia. 2017 Feb;31(2):333-339. doi: 10.1038/leu.2016.234. Epub 2016 Aug 18.

10.

Expanded and armed natural killer cells for cancer treatment.

Shimasaki N, Coustan-Smith E, Kamiya T, Campana D.

Cytotherapy. 2016 Nov;18(11):1422-1434. doi: 10.1016/j.jcyt.2016.06.013. Epub 2016 Aug 3. Review.

PMID:
27497701
11.

Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels.

Mullighan CG, Jeha S, Pei D, Payne-Turner D, Coustan-Smith E, Roberts KG, Waanders E, Choi JK, Ma X, Raimondi SC, Fan Y, Yang W, Song G, Yang JJ, Inaba H, Downing JR, Leung WH, Bowman WP, Relling MV, Evans WE, Zhang J, Campana D, Pui CH.

Blood. 2015 Dec 24;126(26):2896-9. doi: 10.1182/blood-2015-09-671131. Epub 2015 Nov 2. No abstract available.

12.

Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.

Pui CH, Pei D, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE, Inaba H, Bhojwani D, Gruber TA, Leung WH, Downing JR, Evans WE, Relling MV, Campana D.

Lancet Oncol. 2015 Apr;16(4):465-74. doi: 10.1016/S1470-2045(15)70082-3. Epub 2015 Mar 20.

13.

Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.

Karol SE, Coustan-Smith E, Cao X, Shurtleff SA, Raimondi SC, Choi JK, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D, Inaba H.

Br J Haematol. 2015 Jan;168(1):94-101. doi: 10.1111/bjh.13107. Epub 2014 Aug 28.

14.

Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.

Roberts KG, Pei D, Campana D, Payne-Turner D, Li Y, Cheng C, Sandlund JT, Jeha S, Easton J, Becksfort J, Zhang J, Coustan-Smith E, Raimondi SC, Leung WH, Relling MV, Evans WE, Downing JR, Mullighan CG, Pui CH.

J Clin Oncol. 2014 Sep 20;32(27):3012-20.

15.

Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.

Imamura M, Shook D, Kamiya T, Shimasaki N, Chai SM, Coustan-Smith E, Imai C, Campana D.

Blood. 2014 Aug 14;124(7):1081-8. doi: 10.1182/blood-2014-02-556837. Epub 2014 Jul 8.

PMID:
25006133
16.

A revised definition for cure of childhood acute lymphoblastic leukemia.

Pui CH, Pei D, Campana D, Cheng C, Sandlund JT, Bowman WP, Hudson MM, Ribeiro RC, Raimondi SC, Jeha S, Howard SC, Bhojwani D, Inaba H, Rubnitz JE, Metzger ML, Gruber TA, Coustan-Smith E, Downing JR, Leung WH, Relling MV, Evans WE.

Leukemia. 2014 Dec;28(12):2336-43. doi: 10.1038/leu.2014.142. Epub 2014 Apr 30.

17.

Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.

Jeha S, Coustan-Smith E, Pei D, Sandlund JT, Rubnitz JE, Howard SC, Inaba H, Bhojwani D, Metzger ML, Cheng C, Choi JK, Jacobsen J, Shurtleff SA, Raimondi S, Ribeiro RC, Pui CH, Campana D.

Cancer. 2014 May 15;120(10):1514-9. doi: 10.1002/cncr.28598. Epub 2014 Feb 5.

18.

Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.

O'Hear C, Inaba H, Pounds S, Shi L, Dahl G, Bowman WP, Taub JW, Pui CH, Ribeiro RC, Coustan-Smith E, Campana D, Rubnitz JE.

Cancer. 2013 Nov 15;119(22):4036-43. doi: 10.1002/cncr.28334. Epub 2013 Sep 4.

19.

Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia.

Wright KD, Onciu MM, Coustan-Smith E, Campana D, Raimondi SC, Inaba H, Ribeiro R, Pui CH, Sandlund JT.

Pediatr Blood Cancer. 2013 Jul;60(7):E38-41. doi: 10.1002/pbc.24483. Epub 2013 Feb 15.

20.

Should evaluation for minimal residual disease be routine in acute myeloid leukemia?

Coustan-Smith E, Campana D.

Curr Opin Hematol. 2013 Mar;20(2):86-92. doi: 10.1097/MOH.0b013e32835dd90a. Review.

PMID:
23380603
21.

Measurements of treatment response in childhood acute leukemia.

Campana D, Coustan-Smith E.

Korean J Hematol. 2012 Dec;47(4):245-54. doi: 10.5045/kjh.2012.47.4.245. Epub 2012 Dec 24.

22.

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.

Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E, Pui CH, Campana D.

Blood. 2012 Dec 20;120(26):5173-80. doi: 10.1182/blood-2012-07-444042. Epub 2012 Oct 16.

23.

Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

Inaba H, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY, Raimondi SC, Onciu M, Jacobsen J, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D.

J Clin Oncol. 2012 Oct 10;30(29):3625-32. doi: 10.1200/JCO.2011.41.5323. Epub 2012 Sep 10.

24.

Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.

Lapteva N, Durett AG, Sun J, Rollins LA, Huye LL, Fang J, Dandekar V, Mei Z, Jackson K, Vera J, Ando J, Ngo MC, Coustan-Smith E, Campana D, Szmania S, Garg T, Moreno-Bost A, Vanrhee F, Gee AP, Rooney CM.

Cytotherapy. 2012 Oct;14(9):1131-43. doi: 10.3109/14653249.2012.700767. Epub 2012 Aug 17.

25.

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.

Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Shook D, Rubnitz JE, Sandlund JT, Jeha S, Inaba H, Ribeiro RC, Handgretinger R, Laver JH, Campana D.

Blood. 2012 Jul 12;120(2):468-72. doi: 10.1182/blood-2012-02-409813. Epub 2012 Apr 19.

26.

Agammaglobulinemia and absent B lineage cells in a patient lacking the p85α subunit of PI3K.

Conley ME, Dobbs AK, Quintana AM, Bosompem A, Wang YD, Coustan-Smith E, Smith AM, Perez EE, Murray PJ.

J Exp Med. 2012 Mar 12;209(3):463-70. doi: 10.1084/jem.20112533. Epub 2012 Feb 20.

27.

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.

Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, Wei L, Collins-Underwood JR, Ma J, Roberts KG, Pounds SB, Ulyanov A, Becksfort J, Gupta P, Huether R, Kriwacki RW, Parker M, McGoldrick DJ, Zhao D, Alford D, Espy S, Bobba KC, Song G, Pei D, Cheng C, Roberts S, Barbato MI, Campana D, Coustan-Smith E, Shurtleff SA, Raimondi SC, Kleppe M, Cools J, Shimano KA, Hermiston ML, Doulatov S, Eppert K, Laurenti E, Notta F, Dick JE, Basso G, Hunger SP, Loh ML, Devidas M, Wood B, Winter S, Dunsmore KP, Fulton RS, Fulton LL, Hong X, Harris CC, Dooling DJ, Ochoa K, Johnson KJ, Obenauer JC, Evans WE, Pui CH, Naeve CW, Ley TJ, Mardis ER, Wilson RK, Downing JR, Mullighan CG.

Nature. 2012 Jan 11;481(7380):157-63. doi: 10.1038/nature10725.

28.

Clinical significance of early T-cell precursor acute lymphoblastic leukaemia: results of the Tokyo Children's Cancer Study Group Study L99-15.

Inukai T, Kiyokawa N, Campana D, Coustan-Smith E, Kikuchi A, Kobayashi M, Takahashi H, Koh K, Manabe A, Kumagai M, Ikuta K, Hayashi Y, Tsuchida M, Sugita K, Ohara A.

Br J Haematol. 2012 Feb;156(3):358-65. doi: 10.1111/j.1365-2141.2011.08955.x. Epub 2011 Nov 30.

PMID:
22128890
29.

ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.

Bhojwani D, Pei D, Sandlund JT, Jeha S, Ribeiro RC, Rubnitz JE, Raimondi SC, Shurtleff S, Onciu M, Cheng C, Coustan-Smith E, Bowman WP, Howard SC, Metzger ML, Inaba H, Leung W, Evans WE, Campana D, Relling MV, Pui CH.

Leukemia. 2012 Feb;26(2):265-70. doi: 10.1038/leu.2011.227. Epub 2011 Aug 26.

30.

Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.

Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, Heym KM, Christensen R, Onciu M, Shurtleff SA, Pounds SB, Pui CH, Ribeiro RC, Campana D, Baker SD.

J Clin Oncol. 2011 Aug 20;29(24):3293-300. doi: 10.1200/JCO.2011.34.7427. Epub 2011 Jul 18.

31.

Agammaglobulinemia associated with BCR⁻ B cells and enhanced expression of CD19.

Dobbs AK, Bosompem A, Coustan-Smith E, Tyerman G, Saulsbury FT, Conley ME.

Blood. 2011 Aug 18;118(7):1828-37. doi: 10.1182/blood-2011-01-330472. Epub 2011 Jun 21.

32.

High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.

Leung W, Campana D, Yang J, Pei D, Coustan-Smith E, Gan K, Rubnitz JE, Sandlund JT, Ribeiro RC, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Handgretinger R, Laver JH, Pui CH.

Blood. 2011 Jul 14;118(2):223-30. doi: 10.1182/blood-2011-01-333070. Epub 2011 May 25.

33.

New markers for minimal residual disease detection in acute lymphoblastic leukemia.

Coustan-Smith E, Song G, Clark C, Key L, Liu P, Mehrpooya M, Stow P, Su X, Shurtleff S, Pui CH, Downing JR, Campana D.

Blood. 2011 Jun 9;117(23):6267-76. doi: 10.1182/blood-2010-12-324004. Epub 2011 Apr 12.

34.

Improved prognosis for older adolescents with acute lymphoblastic leukemia.

Pui CH, Pei D, Campana D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Coustan-Smith E, Jeha S, Cheng C, Metzger ML, Bhojwani D, Inaba H, Raimondi SC, Onciu M, Howard SC, Leung W, Downing JR, Evans WE, Relling MV.

J Clin Oncol. 2011 Feb 1;29(4):386-91. doi: 10.1200/JCO.2010.32.0325. Epub 2010 Dec 20.

35.

Immunologic minimal residual disease detection in acute lymphoblastic leukemia: a comparative approach to molecular testing.

Coustan-Smith E, Campana D.

Best Pract Res Clin Haematol. 2010 Sep;23(3):347-58. doi: 10.1016/j.beha.2010.07.007. Epub 2010 Oct 28. Review.

36.

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

Rubnitz JE, Inaba H, Dahl G, Ribeiro RC, Bowman WP, Taub J, Pounds S, Razzouk BI, Lacayo NJ, Cao X, Meshinchi S, Degar B, Airewele G, Raimondi SC, Onciu M, Coustan-Smith E, Downing JR, Leung W, Pui CH, Campana D.

Lancet Oncol. 2010 Jun;11(6):543-52. doi: 10.1016/S1470-2045(10)70090-5. Epub 2010 May 5.

37.

Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.

Stow P, Key L, Chen X, Pan Q, Neale GA, Coustan-Smith E, Mullighan CG, Zhou Y, Pui CH, Campana D.

Blood. 2010 Jun 10;115(23):4657-63. doi: 10.1182/blood-2009-11-253435. Epub 2010 Mar 19.

38.

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.

Mullighan CG, Collins-Underwood JR, Phillips LA, Loudin MG, Liu W, Zhang J, Ma J, Coustan-Smith E, Harvey RC, Willman CL, Mikhail FM, Meyer J, Carroll AJ, Williams RT, Cheng J, Heerema NA, Basso G, Pession A, Pui CH, Raimondi SC, Hunger SP, Downing JR, Carroll WL, Rabin KR.

Nat Genet. 2009 Nov;41(11):1243-6. doi: 10.1038/ng.469. Epub 2009 Oct 18.

39.

Minimal residual disease quantitation in acute myeloid leukemia.

Shook D, Coustan-Smith E, Ribeiro RC, Rubnitz JE, Campana D.

Clin Lymphoma Myeloma. 2009;9 Suppl 3:S281-5. doi: 10.3816/CLM.2009.s.024. Review.

40.

Treating childhood acute lymphoblastic leukemia without cranial irradiation.

Pui CH, Campana D, Pei D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Raimondi SC, Onciu M, Coustan-Smith E, Kun LE, Jeha S, Cheng C, Howard SC, Simmons V, Bayles A, Metzger ML, Boyett JM, Leung W, Handgretinger R, Downing JR, Evans WE, Relling MV.

N Engl J Med. 2009 Jun 25;360(26):2730-41. doi: 10.1056/NEJMoa0900386.

41.

Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the children's oncology group.

Coustan-Smith E, Sandlund JT, Perkins SL, Chen H, Chang M, Abromowitch M, Campana D.

J Clin Oncol. 2009 Jul 20;27(21):3533-9. doi: 10.1200/JCO.2008.21.1318. Epub 2009 Jun 22.

42.

Primary B cell immunodeficiencies: comparisons and contrasts.

Conley ME, Dobbs AK, Farmer DM, Kilic S, Paris K, Grigoriadou S, Coustan-Smith E, Howard V, Campana D.

Annu Rev Immunol. 2009;27:199-227. doi: 10.1146/annurev.immunol.021908.132649. Review.

PMID:
19302039
43.

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Coustan-Smith E, Mullighan CG, Onciu M, Behm FG, Raimondi SC, Pei D, Cheng C, Su X, Rubnitz JE, Basso G, Biondi A, Pui CH, Downing JR, Campana D.

Lancet Oncol. 2009 Feb;10(2):147-56. doi: 10.1016/S1470-2045(08)70314-0. Epub 2009 Jan 13.

44.

Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.

Hijiya N, Stewart CF, Zhou Y, Campana D, Coustan-Smith E, Rivera GK, Relling MV, Pui CH, Gajjar A.

Cancer. 2008 May 1;112(9):1983-91. doi: 10.1002/cncr.23395.

45.

WT1 protein expression in childhood acute leukemia.

Kerst G, Bergold N, Gieseke F, Coustan-Smith E, Lang P, Kalinova M, Handgretinger R, Trka J, Müller I.

Am J Hematol. 2008 May;83(5):382-6.

46.

A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.

Flotho C, Coustan-Smith E, Pei D, Cheng C, Song G, Pui CH, Downing JR, Campana D.

Blood. 2007 Aug 15;110(4):1271-7. Epub 2007 Apr 24.

47.

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia.

Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD, Girtman K, Mathew S, Ma J, Pounds SB, Su X, Pui CH, Relling MV, Evans WE, Shurtleff SA, Downing JR.

Nature. 2007 Apr 12;446(7137):758-64.

PMID:
17344859
48.

Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia.

Krampera M, Perbellini O, Vincenzi C, Zampieri F, Pasini A, Scupoli MT, Guarini A, De Propris MS, Coustan-Smith E, Campana D, Foà R, Pizzolo G.

Haematologica. 2006 Aug;91(8):1109-12.

49.

Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.

Flotho C, Coustan-Smith E, Pei D, Iwamoto S, Song G, Cheng C, Pui CH, Downing JR, Campana D.

Blood. 2006 Aug 1;108(3):1050-7. Epub 2006 Apr 20.

50.

A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome.

Coustan-Smith E, Ribeiro RC, Stow P, Zhou Y, Pui CH, Rivera GK, Pedrosa F, Campana D.

Blood. 2006 Jul 1;108(1):97-102. Epub 2006 Mar 14.

Supplemental Content

Loading ...
Support Center